The Latest Breaking News from Oncology

VIJAYAWADA

RBC Capital Market views Gilead Sciences Inc's (NASDAQ:GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite seasonal headwinds, and in-line operating expenses.  The analyst notes that the story remains somewhat catalyst light, especially with transformative M&A likely off the table.  HIV sales,…

MIAMI -- Caring for very sick children daily can be emotionally taxing, even for professionals with years of experience. As front-line workers who also support grieving parents, nurses often cope with chronic stress.

Stephens & Co. has decided to maintain its Equal-Weight rating of Universal Health Services (NYSE:UHS) and lower its price target from $150.00 to $135.00. Shares of Universal Health Services are trading down 0.72% over the last 24 hours, at $124.42 per share.

  Wednesday's session saw 784 companies set new 52-week lows.

Exact Sciences Corp's (NASDAQ:EXAS) Q1 revenues increased 21% Y/Y to $486.6 million, beating the average Wall Street estimate of $461.71 million. Excluding COVID-19 testing revenues, which dropped 15% to $27.4 million, Exact's Q1 revenue increased 24%.  Screening revenues rose 28% to $306.5 million in Q1, while Precision Oncology revenues were up 18%…

Gainers

    On Thursday, 236 companies hit new 52-week lows.